A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
Immunotherapy
Lung cancer
Nivolumab
Nomogram
Prognostic factors
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
27 03 2019
27 03 2019
Historique:
received:
02
01
2019
accepted:
12
03
2019
entrez:
29
3
2019
pubmed:
29
3
2019
medline:
6
5
2020
Statut:
epublish
Résumé
The advent of immune checkpoint inhibitors (ICIs) has considerably expanded the armamentarium against non-small cell lung cancer (NSCLC) contributing to reshaping treatment paradigms in the advanced disease setting. While promising tissue- and plasma-based biomarkers are under investigation, no reliable predictive factor is currently available to aid in treatment selection. Patients with stage IIIB-IV NSCLC receiving nivolumab at Sant'Andrea Hospital and Regina Elena National Cancer Institute from June 2016 to July 2017 were enrolled onto this study. Major clinicopathological parameters were retrieved and correlated with patients' survival outcomes in order to assess their prognostic value and build a useful tool to assist in the decision making process. A total of 102 patients were included in this study. The median age was 69 years (range 44-85 years), 69 (68%) were male and 52% had ECOG PS 0. Loco-regional/distant lymph nodes were the most commonly involved site of metastasis (71%), followed by lung parenchyma (67%) and bone (26%). Overall survival (OS) in the whole patients' population was 83.6%, 63.2% and 46.9% at 3, 6 and 12 months, respectively; while progression-free survival (PFS) was 66.5%, 44.4% and 26.4% at 3, 6 and 12 months, respectively. At univariate analysis, age ≥ 69 years (P = 0.057), ECOG PS (P < 0.001), the presence of liver (P < 0.001), lung (P = 0.017) metastases, lymph nodes only involvement (P = 0.0145) were significantly associated with OS and ECOG PS (P < 0.001) and liver metastases (P < 0.001), retained statistical significance at multivariate analysis. A prognostic nomogram based on three variables (liver and lung metastases and ECOG PS) was built to assign survival probability at 3, 6, and 12 months after nivolumab treatment commencement. We developed a nomogram based on easily available and inexpensive clinical factors showing a good performance in predicting individual OS probability among NSCLC patients treated with nivolumab. This prognostic device could be valuable to clinicians in more accurately driving treatment decision in daily practice as well as enrollment onto clinical trials.
Sections du résumé
BACKGROUND
The advent of immune checkpoint inhibitors (ICIs) has considerably expanded the armamentarium against non-small cell lung cancer (NSCLC) contributing to reshaping treatment paradigms in the advanced disease setting. While promising tissue- and plasma-based biomarkers are under investigation, no reliable predictive factor is currently available to aid in treatment selection.
METHODS
Patients with stage IIIB-IV NSCLC receiving nivolumab at Sant'Andrea Hospital and Regina Elena National Cancer Institute from June 2016 to July 2017 were enrolled onto this study. Major clinicopathological parameters were retrieved and correlated with patients' survival outcomes in order to assess their prognostic value and build a useful tool to assist in the decision making process.
RESULTS
A total of 102 patients were included in this study. The median age was 69 years (range 44-85 years), 69 (68%) were male and 52% had ECOG PS 0. Loco-regional/distant lymph nodes were the most commonly involved site of metastasis (71%), followed by lung parenchyma (67%) and bone (26%). Overall survival (OS) in the whole patients' population was 83.6%, 63.2% and 46.9% at 3, 6 and 12 months, respectively; while progression-free survival (PFS) was 66.5%, 44.4% and 26.4% at 3, 6 and 12 months, respectively. At univariate analysis, age ≥ 69 years (P = 0.057), ECOG PS (P < 0.001), the presence of liver (P < 0.001), lung (P = 0.017) metastases, lymph nodes only involvement (P = 0.0145) were significantly associated with OS and ECOG PS (P < 0.001) and liver metastases (P < 0.001), retained statistical significance at multivariate analysis. A prognostic nomogram based on three variables (liver and lung metastases and ECOG PS) was built to assign survival probability at 3, 6, and 12 months after nivolumab treatment commencement.
CONCLUSION
We developed a nomogram based on easily available and inexpensive clinical factors showing a good performance in predicting individual OS probability among NSCLC patients treated with nivolumab. This prognostic device could be valuable to clinicians in more accurately driving treatment decision in daily practice as well as enrollment onto clinical trials.
Identifiants
pubmed: 30917841
doi: 10.1186/s12967-019-1847-x
pii: 10.1186/s12967-019-1847-x
pmc: PMC6437908
doi:
Substances chimiques
Nivolumab
31YO63LBSN
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
99Références
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Ann Transl Med. 2017 Sep;5(18):376
pubmed: 29057236
Lung Cancer. 2018 Dec;126:217-223
pubmed: 29254746
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S91-S94
pubmed: 29782565
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Immunotargets Ther. 2018 Jul 31;7:63-75
pubmed: 30105218
PLoS One. 2018 Feb 22;13(2):e0192227
pubmed: 29470536
Clin Cancer Res. 2019 Feb 1;25(3):989-999
pubmed: 30206165
Cancer Immunol Res. 2017 May;5(5):417-424
pubmed: 28411193
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Nat Rev Immunol. 2003 Jan;3(1):51-62
pubmed: 12511875
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Transl Med. 2018 Aug 6;16(1):219
pubmed: 30081936
J Thorac Oncol. 2016 Jul;11(7):976-88
pubmed: 26944305
Clin Transl Oncol. 2018 Aug;20(8):1072-1079
pubmed: 29368144
Ann Oncol. 2018 Apr 1;29(4):959-965
pubmed: 29408986